To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70219 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Enrica Antonia Martino und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Onco-Hematology, Cosenza, Italy. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Molecular Targeted Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment. Over the past two decades, however, substantial advances in genomic profiling—including immunoglobulin heavy‐chain variable region (IGHV) mutational status, TP53 disruption, recurrent gene mutations, and complex karyotype—have uncovered marked biological heterogeneity among early‐stage patients and substantially improved prediction of disease progression. In parallel, targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors and venetoclax‐based combinations have transformed the management of symptomatic CLL, raising renewed interest in whether early intervention might favorably alter the natural history of biologically high‐risk disease. In this review, we critically examine the evolution of prognostication in early‐stage CLL, integrate contemporary molecular and clinical risk models, and summarize evidence from both historical chemotherapy‐era studies and modern early‐intervention trials. We discuss key unresolved controversies, including reliance on surrogate endpoints, the risks of overtreatment, and the persistent absence of an overall survival benefit across all early‐treatment strategies. Finally, we outline future research priorities, including refined genomic stratification, minimal residual disease‐driven (MRD)‐driven approaches, and combination targeted therapies currently under investigation. Despite renewed interest in preemptive treatment, available evidence supports continued observation for asymptomatic patients outside clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Department of Onco-Hematology, Cosenza, Italy.
- Molecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
- Department of Experimental Medicine, University of Genoa, Genoa, Italy.
- AIL Sezione di Cosenza, Cosenza, Italy.
- Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
ORCID-Profile: Francesco Mendicino, Franco Fais, Massimo Gentile
Zitieren
APA
Martino, E. A., Caserta, S., Vigna, E., Cutrona, G., Bruzzese, A., Mendicino, F., Alvaro, M. E., Labanca, C., Lucia, E., Olivito, V., Amodio, N., Fais, F., Neri, A., Ferrarini, M., Gattei, V., Morabito, F., & Gentile, M. (2026). To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy. European Journal of Haematology. https://doi.org/10.1111/ejh.70219
Vancouver
Martino EA, Caserta S, Vigna E, Cutrona G, Bruzzese A, Mendicino F, et al. To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy. European Journal of Haematology. 2026. doi:10.1111/ejh.70219
BibTeX
@article{Martino2026,
author = {Martino, Enrica Antonia and Caserta, Santino and Vigna, Ernesto and Cutrona, Giovanna and Bruzzese, Antonella and Mendicino, Francesco and Alvaro, Maria Eugenia and Labanca, Caterina and Lucia, Eugenio and Olivito, Virginia and Amodio, Nicola and Fais, Franco and Neri, Antonino and Ferrarini, Manlio and Gattei, Valter and Morabito, Fortunato and Gentile, Massimo},
title = {To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70219}
}
EUVIMED